Scarica l'app Stockscreener
236.59
1.54%
3.59
Dopo l'orario di chiusura:
236.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$233.00
Aprire:
$234.08
Volume 24 ore:
923.62K
Relative Volume:
0.93
Capitalizzazione di mercato:
$26.11B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
26.10
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
-4.39%
1M Prestazione:
-2.99%
6M Prestazione:
+20.66%
1 anno Prestazione:
+26.64%
Intervallo 1D:
$233.55
$237.29
Intervallo di 1 settimana:
$227.24
$248.84
Portata 52W:
$171.18
$248.84
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
236.59 | 25.72B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 245.99B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 155.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 56.33B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 46.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 44.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - pluang.com
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha
Quest Diagnostics Inc (DGX) Stock Down 4.1% but Still Overvalued -- GF Score: 74/100 - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Before markets open, Quest Diagnostics will report results Oct. 22 - stocktitan.net
Why Quest Diagnostics Holdings Stock Dropped Today - Yahoo Finance
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - Yahoo Finance
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - marketscreener.com
Is This the Right Time to Add DGX Stock to Your Portfolio? - TradingView
Is Quest Diagnostics Stock Outperforming the Nasdaq? - inkl
Evercore sees Lab Corp, Quest shares facing Medicare pricing headwind By Investing.com - Investing.com Canada
Labcorp, Quest fall as CMS cuts 2027 rates for laboratory services (LH:NYSE) - Seeking Alpha
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView
Nearly 1 in 3 people with Lyme antibodies had others too. A parasite found alongside Lyme needs different treatment. - stocktitan.net
Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating - marketscreener.com
CMS to Cut Lab Reimbursement Rates by 15% - Intellectia AI
Quest Diagnostics (DGX) Q1 2026 Earnings Call Transcript - Fortune
Quest Diagnostics stock heads into the open after a flat close - AD HOC NEWS
Quest Diagnostics stock gains on strong second quarter figures and Medicare survey impact - AD HOC NEWS
Quest Diagnostics stock heads into the open after a strong recent gain - AD HOC NEWS
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
96% say lab tests matter as Medicare cuts approach - Stock Titan
A Look at Quest Diagnostics Inc (DGX) After 3.9% Gain -- GF Value $196.33 vs Price $247.08 - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Quest Diagnostics Incorporated (DGX) Stock Is Up Today - Quiver Quantitative
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Has Carved Out a Narrow Moat on Its Attractive Cost Structure - morningstar.com
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
QUEST DIAGNOSTICS INC : UBS RAISES TARGET PRICE TO $245 FROM $232 - webull.com
Quest Diagnostics Announces Apple Health App Users to Be Able to Order Labs from Quest Diagnostics - marketscreener.com
Apple Health users can buy Quest lab tests for $119 later this year - Stock Titan
UBS raises Quest Diagnostics stock price target on durable volumes By Investing.com - Investing.com Canada
UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million - Yahoo Finance
Quest Diagnostics stock edges lower near 52-week highs after solid Q2 growth - ad-hoc-news.de
Man Group takes new $495K stake in Quest Diagnostics as stock nears record high - Dealroom
Quest Diagnostics stock holds steady as investors await next earnings update - ad-hoc-news.de
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX - Yahoo Finance
CEO of Quest Diagnostics (NYSE: DGX) sells 10,000 shares - Stock Titan
Quest Diagnostics Insider Sold Shares Worth $2,427,200, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics stock gains as investors focus on growth and fair value - AD HOC NEWS
Quest Diagnostics stock trades near 52-week high as kidney testing deal lifts valuation - AD HOC NEWS
Quest Diagnostics (NYSE: DGX) insider plans new sale after June $1.9M trade - Stock Titan
Quest Diagnostics SVP & general counsel sells $5.5m in shares - Investing.com Nigeria
Quest Diagnostics SVP & general counsel sells $5.5m in shares By Investing.com - Investing.com South Africa
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Stock Analysis: Navigating Growth Amidst a Competitive Landscape - DirectorsTalk Interviews
Quest Diagnostics stock holds steady as investors await fresh earnings catalysts - AD HOC NEWS
Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares - Stock Titan
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):